Finoriq research workspace
Zentalis Pharmaceuticals, Inc. (ZNTL) Historical Metrics
Zentalis Pharmaceuticals, Inc. develops azenosertib, which is in a Phase 3 clinical trial for the. Review ZNTL fundamentals, ratios, and historical filing metrics on Finoriq.
Company Snapshot
Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers in the United States. It develops azenosertib, which is in a Phase 3 clinical trial for the treatment of ovarian cancer and other tumor types. The company also develops ZN-c3-001, a phase 1 study that evaluated azenosertib monotherapy in solid tumors; and MAMMOTH (ZN-c3-006) is a Phase 1/2 clinical trial of azenosertib in patients with PARP-inhibitor resistant ovarian cancer. It has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC. Zentalis Pharmaceuticals, Inc. was incorporated in 2014 and is based in San Diego, California.
- Company
- Zentalis Pharmaceuticals, Inc. (ZNTL)
- Ticker
- ZNTL
- Market Cap
- $356.6M
- Latest Price
- $5.01
- Industry
- Biotech & Pharma
Zentalis Pharmaceuticals, Inc. (ZNTL) Current Valuation Metrics
Static valuation preview for Zentalis Pharmaceuticals, Inc. (ZNTL). Market data retrieved 2026-07-09. Filing currency USD.
| Metric | Value | Source |
|---|---|---|
| Earnings YieldLatest TTM net income divided by market cap. | -36.7% | Net Income | TTM Q1 2026 |
| Operating Cash Flow YieldLatest TTM operating cash flow divided by market cap. | -37.1% | Operating Cash Flow | TTM Q1 2026 |
| Price / BookMarket cap divided by stockholders' equity. | 1.85x | Stockholders' Equity | Q1 2026 |
Live data loads in the app
This static page shell gives search engines reliable page context. Current tables, filings, charts, and market data continue to load from Finoriq APIs after the application starts.